Global Human Vaccine Market 2016-2020 with GlaxoSmithKline, Merck, Pfizer & Sanofi Dominating

Feb 15, 2016, 08:10 ET from Research and Markets

DUBLIN, Feb. 15, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Human Vaccine Market 2016-2020" report to their offering.

The global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020.

Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines.

A major trend being witnessed in the global human vaccines market is the increase in strategic alliances. Increase in threat from regional vendors in developing countries may cause price erosion and may compel major players to operate under low-margin models. M&A are usually intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company.

According to the report, the growth of the global human vaccines market is driven by the inclusion of several pediatric vaccines in the national immunization schedule of various countries. This helps in increasing the consumption of vaccines. Similarly, the increase in the prevalence of infectious diseases and cancers is also leading to market growth.

Further, the report states that inadequate vaccination coverage is impeding the growth of the market.

Key vendors

- GlaxoSmithKline

- Merck

- Pfizer

- Sanofi

Other prominent vendors

- Abbott

- AstraZeneca

- Bavarian Nordic

- Baxter

- Bharat Biotech

- Bharat Immunologicals and Biologicals

- bioCSL

- Bio Med

- Crucell

- Dynavax Technologies

- Indian Immunologicals

- Janssen Pharmaceuticals

- Kaketsuken

- LG Life Sciences

- Mitsubishi Tanabe Pharma

- Lupin

- Nuron

- Novartis

- Protein Sciences Corporation

- Panacea Biotec

- Roche

- Serum Institute of India

- Shenzhen Kangtai Biological Products

- Sinovac Biotech

- S K Chemicals

- Takeda Pharmaceutical

- Valeant Pharmaceuticals

- Zydus Cadila

Key Topics Covered

PART 01: Executive summary

- Highlights

PART 02: Scope of the report - Market overview - Top-vendor offerings

PART 03: Market research methodology

- Research methodology

- Economic indicators

PART 04: Introduction - Key market highlights

PART 05: Vaccine approval process

- Vaccines price list

PART 06: Pipeline portfolio

PART 07: Market landscape

- Market overview

- Market size and forecast

- Five forces analysis

PART 08: Market segmentation by type of human vaccine - Live attenuated vaccine - Killed vaccine - Toxoid vaccine - Genetically modified/engineered vaccine - Synthetic vaccines - Dendritic cells vaccines - Conjugate vaccines - Subunit vaccines

PART 09: Market segmentation by composition

- Mono vaccine

- Combination vaccines

PART 10: Market segmentation by route of administration - Oral vaccines - Intramuscular vaccines - Intranasal vaccines - Intradermal vaccines

PART 11: Market segmentation by type of human vaccine

PART 12: Global therapeutic human vaccines market - Market overview - Market size and forecast

PART 13: Global preventable human vaccines market

- Market overview

- Market size and forecast

PART 14: Global pediatric preventable human vaccines market - Market size and forecast

PART 15: Global adult preventable human vaccines market

- Market size and forecast

PART 16: Geographical segmentation - Human vaccines market in the Americas - Market size and forecast - Human vaccines market in EMEA - Market size and forecast - Human vaccines market in APAC - Market size and forecast

PART 17: Market drivers

- Growing awareness about vaccination and immunization programs

- Inclusion in national immunization schedule

- High demand for pediatric vaccines

- Increase in prevalence of infectious diseases

PART 18: Impact of drivers

PART 19: Market challenges

- Inadequate vaccination coverage

- Vaccine storage and handling issues

- High risk associated with vaccine development

- Stringent regulatory process

- Misperception about vaccines

- Adverse side effects of vaccines

PART 20: Impact of drivers and challenges

PART 21: Market trends

- Increase in strategic alliance and M&A

- Entry of novel vaccines

- Increase in investment

- Focus on emerging markets

- Emergence of resistant strains

- Public-private initiatives

PART 22: Vendor landscape - Competitive scenario

PART 23: Key vendor analysis


- Sanofi

- Merck

- Pfizer

- Other prominent vendors

PART 24: Appendix

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets